Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactiplantibacillus plantarum DMC-26
- Development stage
- Preclinical
- Lead developer
- DAESANG
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
*Lactiplantibacillus plantarum* DMC-26 is a specific probiotic strain belonging to the species *L. plantarum* (formerly *Lactobacillus plantarum*). Developed by Daesang Corporation, this strain has been investigated primarily for its anti-obesity and metabolic regulatory properties. In preclinical studies, DMC-26 has demonstrated the ability to reduce body weight gain, white adipose tissue accumulation, and serum lipid levels in high-fat diet-induced obese models. Its mechanism of action involves the downregulation of key adipogenic transcription factors, such as peroxisome proliferator-activated receptor gamma (PPAR-γ) and CCAAT/enhancer-binding protein alpha (C/EBPα), while potentially activating the AMP-activated protein kinase (AMPK) pathway to enhance lipid metabolism and energy expenditure.
- Other names
- Lactobacillus plantarum DMC-26L. plantarum DMC-26
02
Targets
PPARG (Peroxisome proliferator-activated receptor gamma)CEBPA (CCAAT enhancer-binding protein alpha)AMPK (Adenosine monophosphate–activated protein kinase)SREBP-1 / SREBF1 (SREBP-1)
Beyond the preview
Go deeper on Lactiplantibacillus plantarum DMC-26.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactiplantibacillus plantarum DMC-26.